Clinical trials: Erythrocytosis, open to volunteers
Clear Cell Renal Cell Carcinoma, Solid Tumors
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of: casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation…
- Trial name
- ARC-20 (NCT05536141)
- Testing
- casdatifan, Cabozantinib, Zimberelimab
- Where
- 25 sites in United States, Australia and 2 more
- Volunteers
- 362 people
- Sponsor
- Arcus Biosciences, Inc.
Erythrocytosis, Pulmonary Hypertension
Phase IIA Study of Belzutifan in EPAS1-, EGLN1-, or VHL-Mutant Erythrocytosis
Some people develop erythrocytosis, a condition characterized by having too many red blood cells, because of inherited changes (mutations) in genes such as EPAS1, EGLN1, or VHL.
- Conditions
- Erythrocytosis, Pulmonary Hypertension, Thrombosis
- Trial name
- NCT07895966
- Testing
- Belzutifan
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Utah
Erythrocytosis, Polycythemia
EVAluation of Erythrocytosis PRospEctive Cohort STudy
The EValuation of ERythrocytosis pRospEctive cohort STudy (EVEREST) is a prospective study designed to shed light on these key questions in the diagnosis, management, and clinical outcomes in patients with elevated hemoglobin…
- Conditions
- Erythrocytosis, Polycythemia, Polycythemia Secondary, Polycythemia Vera
- Trial name
- EVEREST (NCT06785870)
- Where
- Canada
- Volunteers
- 1,500 people
- Sponsor
- Cyrus Hsia